Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy.
作者： Soonmo Peter Kang , Muhammad Wasif Saif
DOI:
关键词:
摘要: Each year, more than 30,000 Americans are diagnosed with pancreatic cancer. We have only made incremental advancements in treatment of cancer despite our best efforts. Research has revealed that is a genetic disease which associated various forms alterations. Identification and understanding these carcinogenic gene alterations the base upon we can overcome drug resistance develop novel approaches. In this paper, review current pharmacogenomics address future direction field.
imedpub.com参考文章(84)
R. G. Moran, C. P. Spears, C. Heidelberger, Biochemical determinants of tumor sensitivity to 5-fluorouracil: Ultrasensitive methods for the determination of 5-fluoro-2′-deoxyuridylate, 2′-deoxyuridylate, and thymidylate synthetase Proceedings of the National Academy of Sciences of the United States of America. ,vol. 76, pp. 1456- 1460 ,(1979) , 10.1073/PNAS.76.3.1456
Ralph H Hruban, Noriyoshi Fukushima, Pancreatic adenocarcinoma: update on the surgical pathology of carcinomas of ductal origin and PanINs. Modern Pathology. ,vol. 20, pp. 61- 70 ,(2007) , 10.1038/MODPATHOL.3800685
Tae Won Kim, Federico Innocenti, Insights, challenges, and future directions in irinogenetics. Therapeutic Drug Monitoring. ,vol. 29, pp. 265- 270 ,(2007) , 10.1097/FTD.0B013E318068623B
Y Nakano, S Tanno, K Koizumi, T Nishikawa, K Nakamura, M Minoguchi, T Izawa, Y Mizukami, T Okumura, Y Kohgo, Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. British Journal of Cancer. ,vol. 96, pp. 457- 463 ,(2007) , 10.1038/SJ.BJC.6603559
Kenji Okumura, Eiji Mekata, Hisanori Shiomi, Hiroyuki Naitoh, Hajime Abe, Yoshihiro Endo, Yoshimasa Kurumi, Tohru Tani, Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer Cancer Chemotherapy and Pharmacology. ,vol. 61, pp. 587- 594 ,(2008) , 10.1007/S00280-007-0511-Y
G. Nishimura, I. Terada, T. Kobayashi, I. Ninomiya, H. Kitagawa, S. Fushida, T. Fujimura, M. Kayahara, K. Shimizu, T. Ohta, K. Miwa, Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncology Reports. ,vol. 9, pp. 479- 482 ,(2002) , 10.3892/OR.9.3.479
A. Beck, M.C. Etienne, S. Chéradame, J.L. Fischel, P. Formento, N. Renée, G. Milano, A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. European Journal of Cancer. ,vol. 30, pp. 1517- 1522 ,(1994) , 10.1016/0959-8049(94)00216-R
C L Huang, H Yokomise, S Kobayashi, M Fukushima, S Hitomi, H Wada, Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. International Journal of Oncology. ,vol. 17, pp. 47- 101 ,(2000) , 10.3892/IJO.17.1.47
James L. Abbruzzese, New applications of gemcitabine and future directions in the management of pancreatic cancer Cancer. ,vol. 95, pp. 941- 945 ,(2002) , 10.1002/CNCR.10753
Sandrine Faivre, Eric Raymond, Jan M. Woynarowski, Esteban Cvitkovic, Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemotherapy and Pharmacology. ,vol. 44, pp. 117- 123 ,(1999) , 10.1007/S002800050955